Titre
Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Burri, E.
Auteure/Auteur
Maillard, M.H.
Auteure/Auteur
Schoepfer, A.M.
Auteure/Auteur
Seibold, F.
Auteure/Auteur
Van Assche, G.
Auteure/Auteur
Rivière, P.
Auteure/Auteur
Laharie, D.
Auteure/Auteur
Manz, M.
Auteure/Auteur
Groupes de travail
Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
Liens vers les personnes
Liens vers les unités
ISSN
1421-9867
Statut éditorial
Publié
Date de publication
2020
Volume
101 Suppl 1
Première page
2
Dernière page/numéro d’article
15
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
Patient care in ulcerative colitis (UC) remains challenging despite an array of established treatment options and emerging new therapies. The management of UC therapy should be guided by the endoscopic extent of inflammation, disease severity, and prognostic factors of poor outcome. Complete remission, defined as durable symptomatic and endoscopic remission without corticosteroid therapy, is the desired treatment goal.
This review focuses on treatment recommendations for different clinical scenarios in moderate-to-severe UC: Active UC of any extent not responding to aminosalicylates, steroid-dependent UC, steroid-refractory UC, immunomodulator-refractory UC, and acute severe UC. Comprehensive treatment algorithms for daily clinical practice were developed based on published guidelines and current literature. Key Messages: While current treatment options including a number of biologicals and small molecules have evolved UC treatment to achieve sustained remission in a majority of patients, upcoming treatment options with different molecular pathways and different modes of actions will further increase the need for personalized medicine.
This review focuses on treatment recommendations for different clinical scenarios in moderate-to-severe UC: Active UC of any extent not responding to aminosalicylates, steroid-dependent UC, steroid-refractory UC, immunomodulator-refractory UC, and acute severe UC. Comprehensive treatment algorithms for daily clinical practice were developed based on published guidelines and current literature. Key Messages: While current treatment options including a number of biologicals and small molecules have evolved UC treatment to achieve sustained remission in a majority of patients, upcoming treatment options with different molecular pathways and different modes of actions will further increase the need for personalized medicine.
PID Serval
serval:BIB_E2C4D2C34AAD
PMID
Open Access
Oui
Date de création
2020-10-20T07:34:35.661Z
Date de création dans IRIS
2025-05-21T00:57:25Z